The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial.
J. R. Berenson
Consultant or Advisory Role - Millennium
Honoraria - Millennium
Research Funding - Cephalon; Millennium
O. Yellin
No relevant relationships to disclose
A. Bessudo
No relevant relationships to disclose
R. Boccia
Research Funding - Center for Cancer and Blood Disorders
S. Noga
Honoraria - Celgene; Centocor Ortho Biotech; Cephalon; Millennium; Takeda
D. Gravenor
Research Funding - Cephalon
D. Patel-Donnelly
No relevant relationships to disclose
R. S. Siegel
Research Funding - Cephalon
T. Kewalramani
No relevant relationships to disclose
E. J. Gorak
No relevant relationships to disclose
R. Swift
Consultant or Advisory Role - Millennium
Honoraria - Millennium
D. Bensen-Kennedy
Employment or Leadership Position - Cephalon
Stock Ownership - Cephalon